[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hoth Therapeutics Inc (HOTH)

Hoth Therapeutics Inc (HOTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,014
  • Shares Outstanding, K 19,128
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,470 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.25
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.80
  • Most Recent Earnings $-0.17 on 05/15/26
  • Next Earnings Date 08/11/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.31
  • Growth Rate Est. (year over year) +322,358.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5400 +151.85%
on 05/19/26
1.5500 -12.26%
on 05/27/26
+0.5800 (+74.36%)
since 04/27/26
3-Month
0.4894 +177.89%
on 04/13/26
1.5500 -12.26%
on 05/27/26
+0.3500 (+34.65%)
since 02/27/26
52-Week
0.4894 +177.89%
on 04/13/26
2.1150 -35.70%
on 09/23/25
+0.5004 (+58.21%)
since 05/27/25

Most Recent Stories

More News
Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications

Company Adopts Space-Focused Identity, New Ticker "RKTO," and Exclusive License of AI Chip Architecture Designed for Ultra-Low-Power, Radiation-Tolerant Computing in Space and Defense Applications

RKTO : 1.5100 (-23.35%)
HOTH : 1.3600 (+92.01%)
Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform

Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce Surface Expression of the High-Affinity IgE Receptor (FcεRI); Strengthens Intellectual Property Foundation...

HOTH : 1.3600 (+92.01%)
AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture

Company Targets Power Demands of AI Data Centers Through Patented Nanomagnetic Semiconductor and Spintronic Computing Technologies for AI, Defense, and Space Applications

HOTH : 1.3600 (+92.01%)
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

Regulatory Clearance in Spain Advances Randomized,  Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment Disruptions

HOTH : 1.3600 (+92.01%)
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide

Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism) Position GDNF as Next-Generation Therapy for MAFLD and Obesity

HOTH : 1.3600 (+92.01%)
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide

Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism) Position GDNF as Next-Generation Therapy for MAFLD and Obesity

HOTH : 1.3600 (+92.01%)
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

NEW YORK , April 2, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today...

HOTH : 1.3600 (+92.01%)
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering

NEW YORK , April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today...

HOTH : 1.3600 (+92.01%)
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six

Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with ~99% Lower Systemic Exposure

HOTH : 1.3600 (+92.01%)
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

Technology Selectively Shuts Down Cancer Reproducing Cells

HOTH : 1.3600 (+92.01%)

Business Summary

Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is...

See More

Key Turning Points

3rd Resistance Point 2.4900
2nd Resistance Point 2.0200
1st Resistance Point 1.6900
Last Price 1.3600
1st Support Level 0.8900
2nd Support Level 0.4200
3rd Support Level 0.0900

See More

52-Week High 2.1150
Fibonacci 61.8% 1.4940
Last Price 1.3600
Fibonacci 50% 1.3022
Fibonacci 38.2% 1.1104
52-Week Low 0.4894

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.